PEDIATRIC EYE DISEASE INVESTIGATOR GROUP: CHAIR'S OFFICE

描述（由申请人提供）：该网络主席办公室申请是儿科眼病研究小组（PEDIG） 5年资金延期的3个平行申请之一。自1997年成立以来，PEDIG已开展了4项斜视治疗方案、19项弱视治疗方案、3项鼻泪管阻塞治疗方案、2项近视/远视治疗方案和若干试点研究。到本申请所要求的资金开始时，预计在当前周期内将启动3个新方案：评估收敛功能不全治疗的随机试验，比较肉毒杆菌毒素与内斜视切口手术的随机试验，以及评估青少年特发性关节炎儿童葡萄膜炎发病率的临床疾病登记。尽管取得了这些成就，许多重要的问题和争议仍然存在于儿童眼保健和斜视。PEDIG已经开发或将开发临床试验来解决这些问题。这些研究包括：(1)在接受最大程度弱视治疗后仍有视力缺陷的儿童的治疗策略；(2)幼儿远视配戴眼镜与不配戴眼镜的效果；(3)间歇性外斜视的最佳手术与非手术治疗方法；(4)白内障手术后并发症的危险因素；(5)最佳治疗方法

DESCRIPTION (provided by applicant): This Network Chair's Office application is one of 3 parallel applications for a five-year extension of funding for the Pediatric Eye Disease Investigator Group (PEDIG). Since its inception in 1997, PEDIG has conducted 4 protocols in strabismus, 19 protocols in amblyopia, 3 protocols in nasolacrimal duct obstruction, 2 protocols in myopia/hyperopia, and several pilot studies. By the time the funding requested in this application would begin, it is expected that 3 new protocols will have started in the current cycle a randomized trial to evaluate treatment for convergence insufficiency, a randomized trial to compare botulinum toxin with incisional surgery for esotropia, and a clinical disease registry to evaluate uveitis incidence in children with juvenile idiopathic arthritis. Despite these accomplishments, many important questions and controversies remain in pediatric eye care and strabismus. PEDIG has developed, or will be developing, clinical trials to address many of these questions. These include: (1) treatment strategies for children with a visual deficit despite maximal amblyopia treatment, (2) the effect of prescribing versus not prescribing spectacles for hyperopia in young children, (3) the best surgical and non-surgical treatments for intermittent exotropia, (4) risk factors for complications after cataract surgery, and (5) the optimal treatment for convergence insufficiency. Specific aims for the next 5-year funding period for PEDIG are to: (1) complete the 7 protocols that are expected to be in progress at the time the funding period begins, (2) initiate 10 new protocols in common pediatric eye disorders where the current management does not have a proven rationale, (3) continue to expand the PEDIG network by soliciting the participation of new sites and investigators and encouraging the involvement of young investigators, (4) continue to educate pediatric ophthalmologists, pediatric optometrists, and clinical research coordinators on the principles of clinical trials and good clinical research practices, (5) train pediatric ophthalmologists and pediatric optometrists to be leaders in clinica trials and clinical research, and (6) develop new methods and outcome measures needed to conduct future amblyopia and strabismus trials.